Anti Cancer Drugs

Breast cancer, a disease long associated with older age groups, has surged enormously in women aged below 50 in the last three decades, according to experts. Breast cancer is the most common type of cancer affecting women worldwide, as well as in India. The recent data from the Indian Council of Medical Research (ICMR) showed that breast cancer accounted for 28.2 per cent of cancers in women. Celebrities like Sonali Bendre, Tahira Kashyap, and Mahima Chaudhry who battled breast cancer under 50 and overcame the deadly disease with treatments. Dr Ashish Gupta, Chief of Medical Oncology at Unique Hospital Cancer Centre, who is spearheading the Cancer Mukt Bharat Campaign in India, said "Cancer is no longer the disease of older adults. It is increasingly seen among women in the younger age group, majorly under 50. The early onset of breast cancer is majorly due to genes, lifestyle factors such as poor nutrition, consumption of highly ultra-processed foods and a completely sedentary ..

.

The facility, which will be the drugmaker's first end-to-end ADC production site, will be supported by the Singapore Economic Development Board

Zydus Lifesciences Ltd on Friday announced an exclusive licensing and supply agreement with MSN Laboratories for generic cancer treatment drug Cabozantinib tablets, for the US market. The company's wholly-owned subsidiary, Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with MSN Laboratories for Cabozantinib tablets for the US market, Zydus Lifesciences Ltd said in a regulatory filing. Cabozantinib tablet is the generic version of CABOMETYX of Exelixis. Under the agreement, MSN Laboratories will be in charge of manufacturing and supplying the generic version of CABOMETYX, following the receipt of regulatory approval, the company said. Zydus will exclusively market, distribute, and sell the product in the US market, it added. "MSN was a first sole ANDA (abbreviated new drug application) applicant for Cabozantinib tablets, to submit a substantially complete ANDA with a paragraph IV certification and therefore may be eligible for 180 days o

The U.S. Food and Drug Administration's accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients' lives? In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such benefits within five years. Five years after the initial accelerated approval, you should have a definitive answer, said Dr. Ezekiel Emanuel, a cancer specialist and bioethicist at the University of Pennsylvania who was not involved in the research. Thousands of people are getting those drugs. That seems a mistake if we don't know whether they work or not." The program was created in 1992 to speed access to HIV drugs. Today, 85% of accelerated approvals go to cancer drugs. It allows the FDA to grant early approval to drugs that show promising initial results for treating debilitating or fatal diseases. In exchange, drug companies are expected to do rigorous testing and produce

Aurobindo Pharma on Friday said its wholly-owned arm, Eugia Pharma Specialities Ltd has entered into a voluntary sub-licensing agreement with Medicines Patent Pool (MPP) to develop and market an anti-cancer drug. The sub-licensing agreement for Nilotinib capsules, originally developed by Novartis, will be in 44 low and middle-income countries (LMIC), including the seven countries where patents on the product are pending or in force, Aurobindo Pharma said in a regulatory filing. Nilotinib capsules are used for treatment of chronic myeloid leukemia. "These are the first sub-licence agreements that MPP has signed for a cancer treatment that will be made available in the LMIC, through this licence. This product will be a good addition to Aurobindo's Oncology portfolio and will further strengthen our leadership in the generic Oncology medicine space," Aurobindo Pharma Vice Chairman & Managing Director K Nithyananda Reddy said. He further said,"We are looking forward to start supplying .

As many as 34 new drugs were added and 26 dropped from an updated list of essential medicines that will lead to prices being fixed, said the government on Tuesday.

Thirty-four drugs, including some anti-infectives such as Ivermectin, Mupirocin and Nicotine Replacement Therapy, have been added to the National List of Essential Medicines taking the total drugs under it to 384. Several antibiotics, vaccines and anti-cancer drugs will become more affordable by their addition to the list. However, 26 drugs such as Ranitidine, Sucralfate, white petrolatum, Atenolol and Methyldopa have been deleted from the revised list. The deletion has been done based on the parameters of cost effectiveness and availability of better drugs. Union Health Minister Mansukh Mandaviya, who released the list on Tuesday, tweeted, "Released the National List of Essential Medicines 2022.It comprises 384 drugs across 27 categories.Several antibiotics, vaccines, anti-cancer drugs and many other important drugs will become more affordable & reduce patients' out-of-pocket expenditure." Endocrine medicines and contraceptives Fludrocortisone, Ormeloxifene, Insulin Glargine and

The inclusion of this vaccine in the NIM is a significant step in reducing cervical cancer burden among women

A group of scientists in the US, including an Indian-American from the prestigious Cleveland Clinic, have identified a potential new class of drugs that may prove effective in treating certain common types of blood and bone marrow cancers. First published in the latest edition of Blood Cancer Discovery, the decade long research which reports that a new pharmacological strategy to preferentially target and eliminate leukemia cells with TET2 mutations, was carried out by Jaroslaw Maciejewski and his collaborator Babal Kant Jha from the Cleveland Clinic Department of Translational Hematology & Oncology Research. Myeloid leukemias are cancers derived from stem and progenitor cells in the bone marrow that give rise to all normal blood cells. One of the most common mutations involved in driving myeloid leukemias are found in the TET2 gene, which has been investigated for the last decade by Maciejewski and Jha. In preclinical models, we found that a synthetic molecule called TETi76 was ..

The UK drugmaker will pay Japan's Daiichi $1 billion upfront to jointly develop and bring to market a cancer therapy in early clinical tests called DS-1062, the companies said

"We found that a surprising number of non-oncology drugs are able to kill cancer cell lines in the lab," said Steven Corsello of Dana-Farber Cancer Institute

Researchers, including those from the University of Sheffield in the UK, assessed the effect of drugs used to treat different cancer types on lung damage in people living with COPD

Lupin will get the marketing rights for the drug in India, while Boehringer Ingelheim will hold the rights to all other markets

The NPPA has the right to cap prices of scheduled drugs, or use extraordinary powers in case of other drugs